Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZL-1218 |
| Synonyms | |
| Therapy Description |
ZL-1218 is an anti-CCR8 antibody, which potentially induces antibody-dependent cellular cytotoxicity against CCR8-expressing T-regulatory cells and inhibition of tumor growth (Cancer Res (2022) 82 (12_Supplement): 3590). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZL-1218 | ZL 1218|ZL1218 | CCR8 Antibody 13 | ZL-1218 is an anti-CCR8 antibody, which potentially induces antibody-dependent cellular cytotoxicity against CCR8-expressing T-regulatory cells and inhibition of tumor growth (Cancer Res (2022) 82 (12_Supplement): 3590). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05859464 | Phase I | Pembrolizumab + ZL-1218 ZL-1218 | A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors | Terminated | USA | ESP | 1 |